Yahoo Finance Insider Sale: COO Heather Prichard Divests All Shares in Humacyte Inc (HUMA)
On May 31, 2024, Heather Prichard, Chief Operating Officer of Humacyte Inc (NASDAQ:HUMA), sold 191,511 shares of the company, according to the SEC Filing. Following this transaction, the insider now owns 0 shares of Humacyte Inc.
Humacyte Inc, a biotechnology company, focuses on developing and manufacturing human acellular vessels for multiple therapeutic areas. The company's innovative approach aims to improve treatment outcomes for patients suffering from vascular and other diseases.
The transaction occurred with the shares priced at $8.15, valuing the sale at approximately $1,560,414.65. This sale has adjusted the insider's stake in the company to zero, marking a significant change in their investment position.
Over the past year, Heather Prichard has sold a total of 191,511 shares and has not made any purchases. This pattern of selling is part of a broader trend within the company. In the past year, there have been 11 insider sells and only 3 insider buys at Humacyte Inc.
The market cap of Humacyte Inc stands at $877.65 million as of the latest trading session. The company's valuation metrics, such as the GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow are key indicators for investors to assess the stock's potential.
The insider transaction trends at Humacyte Inc suggest a predominance of selling activities over buying among the insiders, which could be an area of interest for potential investors and market analysts observing the company's stock performance and insider confidence levels.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
